Want to see HRGN full AI Analyst Report?
Top Page
Harvard Apparatus Regenerative Technology
(OTC:HRGN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-5.06% Downside)
Action:Reiterated
Date:08/17/26
HRGN scores low primarily due to very weak financial performance—large losses, persistent cash burn, and negative equity. Technicals provide some support from recent upward momentum, but overbought signals add near-term risk. Valuation is also constrained by negative earnings and no dividend yield data.
Positive Factors
Strong Revenue Growth
Revenue growth indicates improving commercialization after several years of near-zero sales. Sustained adoption could provide a foundation for operating leverage, although the company must still convert growth into viable margins and cash flow.
Negative Factors
Severe Unprofitability
Losses are exceptionally large relative to revenue, while negative gross profit shows the core economics are not yet viable. Without substantial cost reduction or pricing improvement, additional revenue may continue increasing activity without producing sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Revenue growth indicates improving commercialization after several years of near-zero sales. Sustained adoption could provide a foundation for operating leverage, although the company must still convert growth into viable margins and cash flow.
Read all positive factors
Harvard Apparatus Regenerative Technology (HRGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$40.44M
Dividend YieldN/A
Average Volume (3M)709.00
Price to Earnings (P/E)―
Beta (1Y)-0.37
Revenue Growth44.62%
EPS Growth9.81%
CountryUS
Employees8
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,580,744
10 Day Avg. Volume219
30 Day Avg. Volume709
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)28.75
Price to Sales (P/S)43.17
P/FCF Ratio-7.94
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue21.61
Enterprise Value/Gross Profit-40.10
Enterprise Value/Ebitda-2.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Harvard Apparatus Regenerative Technology Business Overview & Revenue Model
Company Description
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal sy...
How the Company Makes Money
null...
Harvard Apparatus Regenerative Technology Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 859.00K | 704.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -463.00K | 58.00K | -270.00K | -24.00K | 0.00 | 0.00 |
| EBITDA | -6.57M | -6.76M | -8.16M | -9.09M | -5.92M | -8.53M |
| Net Income | -6.68M | -6.87M | -7.73M | -9.02M | -6.07M | -7.98M |
Balance Sheet | ||||||
| Total Assets | 1.69M | 2.68M | 4.44M | 2.61M | 2.40M | 1.87M |
| Cash, Cash Equivalents and Short-Term Investments | 351.00K | 1.35M | 2.49M | 432.00K | 1.24M | 1.24M |
| Total Debt | 645.00K | 199.00K | 294.00K | 48.00K | 147.00K | 169.00K |
| Total Liabilities | 3.06M | 1.62M | 1.22M | 968.00K | 1.41M | 4.89M |
| Stockholders Equity | -1.38M | 1.06M | 3.22M | 1.65M | 989.00K | -3.03M |
Cash Flow | ||||||
| Free Cash Flow | -3.63M | -3.83M | -4.85M | -6.95M | -5.11M | -2.63M |
| Operating Cash Flow | -3.63M | -3.83M | -4.85M | -6.94M | -5.11M | -2.63M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -11.00K | -5.00K | 0.00 |
| Financing Cash Flow | 3.20M | 2.70M | 6.91M | 6.14M | 5.06M | 2.84M |
Harvard Apparatus Regenerative Technology Technical Analysis
Positive
1.58
Price Trends
1.26
Positive
1.33
Positive
1.55
Positive
Market Momentum
0.22
Negative
89.70
Negative
59.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Positive. The current price of 1.58 is above the 20-day moving average (MA) of 1.51, above the 50-day MA of 1.26, and above the 200-day MA of 1.55, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 89.70 is Negative, neither overbought nor oversold. The STOCH value of 59.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRGN.
Harvard Apparatus Regenerative Technology Risk Analysis
Harvard Apparatus Regenerative Technology disclosed 49 risk factors in its most recent earnings report. Harvard Apparatus Regenerative Technology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Harvard Apparatus Regenerative Technology Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
47 Neutral | $40.44M | -5.91 | -2019.03% | ― | 44.62% | 9.81% | |
47 Neutral | $30.46M | -0.65 | -223.19% | ― | -42.74% | 20.66% | |
44 Neutral | $53.84M | -0.50 | 411.46% | ― | -51.03% | -35.20% | |
40 Underperform | $5.14M | -0.12 | -423.84% | ― | -8.47% | 25.61% | |
27 Underperform | $17.53M | -0.48 | 203.55% | ― | 4.35% | 20.37% |
* Consumer Defensive Sector Average
HRGN
Harvard Apparatus Regenerative Technology
2.35
0.57
32.02%
PLUR
Pluri
1.37
-3.48
-71.75%
BRTX
BioRestorative Therapies
0.14
-1.49
-91.23%
CELZ
Creative Medical Technology Holdings
1.06
-2.23
-67.78%
CELU
Celularity
1.83
-0.53
-22.46%
LGVN
Longeveron
6.58
-0.90
-12.04%
Harvard Apparatus Regenerative Technology Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Harvard Apparatus Secures Second Insider Bridge Loan Financing
Neutral
Aug 3, 2026
On May 8, 2026, Harvard Apparatus Regenerative Technology, Inc. entered into a $200,000 bridge loan with its chairman and CEO, Junli He, under a note bearing 8% annual interest and maturing on the earlier of the next capital raise of at least $5 m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.